14954-2 |
Xylose^post dose PO |
SRat |
Urine |
5H |
Qn |
|
|
ACTIVE |
Xylose [Moles/time] in 5 hour Urine --post dose PO |
|
MIN |
DefinitionDescription |
|
|
mmol/5 H |
|
|
|
|
|
|
CHAL |
|
14954-2 |
|
|
|
|
Observation |
|
|
|
0 |
Xylose p PO 5h Ur-sRate |
|
|
|
Y |
|
5 hours; 5.0Hr; 5HR; After; CHEMISTRY.CHALLENGE TESTING; D-xylose; p dose; p PO; PST; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn; Xylose absorption test |
2.4 |
1.0k |
|
|
|
|
|
|
|
mmol/(5.h) |
|
|
|
0 |
14955-9 |
Zinc |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Zinc [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14955-9 |
|
|
|
|
Both |
|
|
|
0 |
Zinc SerPl-sCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Zn |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14956-7 |
Albumin |
MRat |
Urine |
24H |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin [Mass/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
ug/24 H |
|
|
|
|
|
|
CHEM |
|
14956-7 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin 24h Ur-mRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Alb; Chemistry; DL=20 mg/L; Kidney; Left; Levo; MA; Malb; Mass rate; Micro albumin; Microalbumin; mRate; Nephrology; Protein.albumin; QNT; Quan; Quant; Quantitative; Renal; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
mg/(24.h) |
|
|
|
0 |
14957-5 |
Albumin |
MCnc |
Urine |
Pt |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/L;mcg/mL; mg/dL |
|
|
|
|
|
|
CHEM |
|
14957-5 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin Ur-mCnc |
|
|
|
Y |
|
Alb; Chemistry; DL=20 mg/L; Kidney; Left; Level; Levo; MA; Malb; Mass concentration; Micro albumin; Microalbumin; Nephrology; Point in time; Protein.albumin; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UniversalLabOrders; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
ug/mL;mg/dL |
|
|
|
0 |
14958-3 |
Albumin/Creatinine |
MRto |
Urine |
24H |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin/Creatinine [Mass Ratio] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
CHEM |
|
14958-3 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin/Creat 24h Ur |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Alb; Chemistry; CR; Crea; Creat; DL=20 mg/L; Kidney; Left; Levo; MA; Malb; Mass concentration ratio; Mass ratio; MCRto; Micro albumin; Microalbumin; Nephrology; Protein.albumin; QNT; Quan; Quant; Quantitative; Renal; UA; UCr; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
14959-1 |
Albumin/Creatinine |
MRto |
Urine |
Pt |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
CHEM |
|
14959-1 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin/Creat Ur |
|
|
|
Y |
|
Alb; Chemistry; CR; Crea; Creat; DL=20 mg/L; Kidney; Left; Levo; MA; Malb; Mass concentration ratio; Mass ratio; MCRto; Micro albumin; Microalbumin; Nephrology; Point in time; Protein.albumin; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UCr; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
1496-9 |
Glucose^1.5H post 75 g glucose PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1496-9 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 1.5h p 75 g Glc PO SerPl-mCnc |
|
|
|
Y |
|
1 1/2 hours; 1 1/2 HR; 1.5h p 75 g Glc PO; 1.5Hr; 75Gm; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 75 g Glc PO; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
14960-9 |
Estradiol.free/Estradiol.total |
MFr |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Estradiol (E2) Free/Estradiol (E2).total in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
14960-9 |
|
|
|
|
Observation |
|
|
|
0 |
Estradiol Free MFr SerPl |
|
|
|
Y |
|
17-beta estradiol; Chemistry; E2; Estradiol Free; Estradiol.non-protein bound; FR; Gyn; Gynecology; Mass Fraction; Non-protein bound; OB; ObGyn; Obstetrics; Oestradiol; Percent; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tot; Totl |
2.73 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14961-7 |
Abnormal blood cells.CD10/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD10 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14961-7 |
|
|
|
|
Observation |
|
|
|
0 |
CD10 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Blood; CALLA; CD10 Abn Bld Cells; CD10 Cells; Cell; CELL MARKERS; Cellularity; Common acute lymphoblastic leukemia; Common acute lymphoblastic leukemia antigen; Enkephalinase; gp100; J5; NEP; Neprilysin; Neutral endopeptidase metalloendopeptidase; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14962-5 |
Abnormal blood cells.CD13/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD13 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14962-5 |
|
|
|
|
Observation |
|
|
|
0 |
CD13 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Aminopeptidase n; APN; Blood; CD13 Abn Bld Cells; CD13 Cells; Cell; CELL MARKERS; Cellularity; gp150; LeuM7; Leu-M7; My7; My-7; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14963-3 |
Abnormal blood cells.CD14/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD14 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14963-3 |
|
|
|
|
Observation |
|
|
|
0 |
CD14 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Blood; CD14 Abn Bld Cells; CD14 Cells; Cell; CELL MARKERS; Cellularity; LeuM3; Leu-M3; LPS receptor; LPS-R; Mo2; Mo-2; My4; My-4; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14964-1 |
Abnormal blood cells.CD19/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD19 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14964-1 |
|
|
|
|
Both |
|
|
|
0 |
CD19 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; B cells expressing CD19 as a percent of total lymphocytes; B4; B-4; Blood; CD19 Abn Bld Cells; CD19 Cells; Cell; CELL MARKERS; Cellularity; HD-37; Leu12; Leu-12; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.73 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14965-8 |
Abnormal blood cells.CD2/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD2 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14965-8 |
|
|
|
|
Observation |
|
|
|
0 |
CD2 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Blood; CD2 Abn Bld Cells; CD2 Cells; CD2R; Cell; CELL MARKERS; Cellularity; E-rosette receptor; Leu5; Leu-5; LFA-2; Lymphocyte-function antigen-2; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; T11; Tot; Totl; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14966-6 |
Abnormal blood cells.CD20/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD20 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14966-6 |
|
|
|
|
Observation |
|
|
|
0 |
CD20 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; B1; B-1; Blood; Bp35; CD20 Abn Bld Cells; CD20 Cells; Cell; CELL MARKERS; Cells.CD20+; Cellularity; Leu16; Leu-16; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14967-4 |
Abnormal blood cells.CD33/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD33 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14967-4 |
|
|
|
|
Observation |
|
|
|
0 |
CD33 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Blood; CD33 Abn Bld Cells; CD33 Cells; Cell; CELL MARKERS; Cellularity; gp67; LeuM9; Leu-M9; My9; My-9; Number fraction; p67; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14968-2 |
Abnormal blood cells.CD5/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD5 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14968-2 |
|
|
|
|
Observation |
|
|
|
0 |
CD5 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Blood; CD5 Abn Bld Cells; CD5 Cells; Cell; CELL MARKERS; Cellularity; Leu1; Leu-1; Ly-1; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; T1; Tot; Totl; Tp67; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14969-0 |
Abnormal blood cells.CD7/Abnormal blood cells.total |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD7 Abnormal blood cells/Abnormal blood cells.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
14969-0 |
|
|
|
|
Observation |
|
|
|
0 |
CD7 Abn Bld Cells NFr |
|
|
|
Y |
|
abn; abnorm; Blood; CD7 Abn Bld Cells; CD7 Cells; Cell; CELL MARKERS; Cellularity; gp40; Leu9; Leu-9; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; T-2; Tot; Totl; TP41; WB; Whole blood |
2.7 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
1497-7 |
Glucose^1.5H post dose insulin IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose insulin IV |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1497-7 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 1.5h p Ins IV SerPl-mCnc |
|
|
|
Y |
|
1 1/2 hours; 1 1/2 HR; 1.5h p Ins IV; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
14970-8 |
Estrone.bioavailable |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Estrone (E1).bioavailable [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHEM |
|
14970-8 |
|
|
|
|
Both |
|
|
|
0 |
Estrone Bioavail SerPl-mCnc |
|
|
|
Y |
|
Chemistry; E1; Estrone Bioavail; Gyn; Gynecology; Level; Mass concentration; OB; ObGyn; Obstetrics; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
14971-6 |
Estrone.bioavailable/Estrone.total |
MFr |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Estrone (E1).bioavailable/Estrone (E1).total in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
14971-6 |
|
|
|
|
Observation |
|
|
|
0 |
Estrone Bioavail MFr SerPl |
|
|
|
Y |
|
Chemistry; E1; Estrone Bioavail; Gyn; Gynecology; Mass Fraction; OB; ObGyn; Obstetrics; Percent; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tot; Totl |
2.73 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
14972-4 |
Mycobacterium sp DNA |
PrThr |
CSF |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycobacterium sp DNA [Presence] in Cerebral spinal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
14972-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Mycobacterium DNA CSF Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Amplif; Amplification; Amplified; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Myco; Mycobact; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; species; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; spp; Strand Displacement Amplification; TMA; Transcription mediated amplification; Tuberculosis |
2.63 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14973-2 |
Mycobacterium sp DNA |
PrThr |
Sputum |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycobacterium sp DNA [Presence] in Sputum by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
14973-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Mycobacterium DNA Spt Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lower respiratory; Lung; Microbiology; Myco; Mycobact; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Pulmonary; Pulmonology; QBR; QL; Qual; Qualitative; Random; Respiratory; Screen; SDA; species; spp; Spt; Sputum; Strand Displacement Amplification; TMA; Transcription mediated amplification; Tuberculosis |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14974-0 |
Mycobacterium sp DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycobacterium sp DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
14974-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Mycobacterium DNA Spec Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; Myco; Mycobact; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; species; spp; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Tuberculosis; Unspecified |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14975-7 |
Human antimouse Ab |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Human antimouse Ab [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
SERO |
|
14975-7 |
|
|
|
|
Both |
|
|
|
0 |
Human Antimouse Ab Ser-mCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Anti-Mouse; Autoantibodies; Autoantibody; HAMA; Human Anti-monoclonal AB; Human anti-mouse Ab; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
14976-5 |
Lecithin/Sphingomyelin |
Ratio |
Amnio fld |
Pt |
Qn |
|
|
ACTIVE |
Lecithin/Sphingomyelin [Ratio] in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
14976-5 |
|
|
|
|
Both |
|
|
|
0 |
Lecithin/Sphingomyelin Amn-Rto |
|
|
|
Y |
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; c470; Chemistry; Choline phosphoglyceride; Phosphatidylcholine; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; SPH; UniversalLabOrders |
2.73 |
1.0k |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |